Merck, Glenmark Fight Zetia Class Cert. At 4th Circ.

By Julia Arciga ( January 5, 2021, 6:21 PM EST) -- Drugmakers Merck and Glenmark have asked the Fourth Circuit to reverse the class certification of direct buyers of cholesterol drug Zetia, stating the named plaintiffs were unfit to represent the class and the other members' circumstances did not warrant class status....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!